BR112013032841A8 - Method for producing powders for inhalation - Google Patents

Method for producing powders for inhalation

Info

Publication number
BR112013032841A8
BR112013032841A8 BR112013032841A BR112013032841A BR112013032841A8 BR 112013032841 A8 BR112013032841 A8 BR 112013032841A8 BR 112013032841 A BR112013032841 A BR 112013032841A BR 112013032841 A BR112013032841 A BR 112013032841A BR 112013032841 A8 BR112013032841 A8 BR 112013032841A8
Authority
BR
Brazil
Prior art keywords
inhalation
active ingredient
mixing
powders
producing powders
Prior art date
Application number
BR112013032841A
Other languages
Portuguese (pt)
Other versions
BR112013032841B1 (en
BR112013032841A2 (en
Inventor
Shinichi Ono
Original Assignee
Clinipro Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clinipro Co Ltd filed Critical Clinipro Co Ltd
Publication of BR112013032841A2 publication Critical patent/BR112013032841A2/en
Publication of BR112013032841A8 publication Critical patent/BR112013032841A8/en
Publication of BR112013032841B1 publication Critical patent/BR112013032841B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

método para a produção de pós para inalação. [problemas] a presente invenção fornece um método para a produção de pós para inalação, em que o desvio é menor na distribuição e a capacidade de dispersão é excelente. [soluções] a presente invenção se refere a um método para a produção de pós para inalação, compreendendo: uma primeira etapa de mistura de agitação de um primeiro ingrediente ativo e um carreador na presença de um meio de moagem, e mistura do primeiro ingrediente ativo e do carreador ao desintegrar os 'aglomerados do primeiro ingrediente ativo para obter uma mistura do carreador e do primeiro ingrediente ativo; e uma segunda etapa de adição de pós finos para a mistura obtida na primeira etapa de mistura, e agitação e mistura da mistura e dos pós finos na presença de um meio de moagem.method for producing powders for inhalation. [Problems] The present invention provides a method for producing powders for inhalation, where the deviation is smaller in the distribution and the dispersibility is excellent. [solutions] The present invention relates to a method for producing powders for inhalation, comprising: a first step of stirring mixing a first active ingredient and a carrier in the presence of a milling medium, and mixing the first active ingredient and the carrier by disintegrating the agglomerates of the first active ingredient to obtain a mixture of the carrier and the first active ingredient; and a second step of adding fine powders to the mixture obtained in the first mixing step, and stirring and mixing the mixture and fine powders in the presence of a milling medium.

BR112013032841-0A 2012-06-13 2013-02-25 Method for producing powders for inhalation BR112013032841B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012134171A JP5087182B1 (en) 2012-06-13 2012-06-13 Method for producing inhalable powder
JP2012-134171 2012-06-13
PCT/JP2013/054710 WO2013187088A1 (en) 2012-06-13 2013-02-25 Method for producing powder for inhalation

Publications (3)

Publication Number Publication Date
BR112013032841A2 BR112013032841A2 (en) 2017-02-21
BR112013032841A8 true BR112013032841A8 (en) 2021-09-08
BR112013032841B1 BR112013032841B1 (en) 2022-04-05

Family

ID=47435636

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013032841-0A BR112013032841B1 (en) 2012-06-13 2013-02-25 Method for producing powders for inhalation

Country Status (12)

Country Link
US (1) US9532958B2 (en)
EP (1) EP2716281B1 (en)
JP (1) JP5087182B1 (en)
CN (1) CN103619326B (en)
AU (1) AU2013275641B2 (en)
BR (1) BR112013032841B1 (en)
CA (1) CA2840372C (en)
IL (1) IL229834B (en)
NZ (1) NZ620714A (en)
PT (1) PT2716281T (en)
RU (1) RU2013154972A (en)
WO (1) WO2013187088A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5266335B2 (en) 2008-01-31 2013-08-21 エクソンモービル・ケミカル・パテンツ・インク Improved utilization of linear alpha olefins in the production of poly-alpha olefins over metallocene catalysts
JP6116206B2 (en) * 2012-11-26 2017-04-19 クリニプロ株式会社 Method for producing inhalable powder
CN108066329B (en) * 2016-11-11 2021-11-16 江苏恒瑞医药股份有限公司 Preparation method of microparticles of fluticasone or derivatives thereof for inhalation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4140689B4 (en) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalable powders and process for their preparation
JP2001151673A (en) * 1999-09-06 2001-06-05 Nikken Chem Co Ltd Production of powdery preparation for inhalation
WO2001026630A1 (en) * 1999-10-12 2001-04-19 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
GB0010709D0 (en) * 2000-05-03 2000-06-28 Vectura Ltd Powders for use a in dry powder inhaler
ATE424811T1 (en) 2000-08-31 2009-03-15 Jagotec Ag GROUND PARTICLES
CA2430318C (en) * 2000-11-29 2009-10-27 Itoham Foods Inc. Powder formulation and method for producing the same
ES2689704T3 (en) * 2000-11-30 2018-11-15 Vectura Limited Particles for use in a pharmaceutical composition
JP4744876B2 (en) 2002-08-21 2011-08-10 ノートン・ヘルスケアー リミテッド Method for producing a dry powder inhalation composition
US20050158248A1 (en) 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
US7230012B2 (en) 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
JO3102B1 (en) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A Pharmaceutical formulations for dry powder inhalers comprising a low- dosage strength active ingredient
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
EP1973523A2 (en) * 2005-12-15 2008-10-01 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
GB0714134D0 (en) 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
CN101422436B (en) * 2007-10-31 2010-12-01 江苏正大天晴药业股份有限公司 Dry powder composite for suction
US20110105449A1 (en) 2007-11-07 2011-05-05 Astrazeneca R&D Dry powder formulations comprising ascorbic acid derivates
JP2009279558A (en) 2008-05-26 2009-12-03 Sumitomo Wiring Syst Ltd Mixing device
EP2571486A4 (en) * 2010-05-20 2013-12-04 Sun Pharma Advanced Res Co Ltd Dry powder inhalation composition

Also Published As

Publication number Publication date
US20140134254A1 (en) 2014-05-15
CN103619326B (en) 2018-05-22
PT2716281T (en) 2020-11-19
IL229834A0 (en) 2014-03-31
RU2013154972A (en) 2015-06-20
BR112013032841B1 (en) 2022-04-05
EP2716281A4 (en) 2015-08-26
JP2013255708A (en) 2013-12-26
EP2716281A1 (en) 2014-04-09
CA2840372C (en) 2017-12-12
JP5087182B1 (en) 2012-11-28
BR112013032841A2 (en) 2017-02-21
CN103619326A (en) 2014-03-05
AU2013275641B2 (en) 2017-02-02
US9532958B2 (en) 2017-01-03
AU2013275641A1 (en) 2014-02-27
NZ620714A (en) 2017-01-27
IL229834B (en) 2019-12-31
EP2716281B1 (en) 2020-09-30
CA2840372A1 (en) 2013-12-19
WO2013187088A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
MX2020012596A (en) Processes and intermediates for preparing a medicament.
BR112014029754B1 (en) surfactant solutions containing n-methyl-noleylglucamines and n-methyl-n-c12-c14 acylglucamines and their use, process for producing cosmetic compositions and composition
BR112013020513A2 (en) highly soluble stevia sweetener
BR112015005940A2 (en) process for the preparation of therapeutic nanoparticles
BR112013023517A2 (en) "leukotriene production inhibitors, their uses, and pharmaceutical composition"
BR112013000254A2 (en) 1-phenyl-substituted heterocyclic derivatives and their use as prostaglandin d2 receptor modulators
BR112015023153A2 (en) use of a compound and compound
BR112015023142A2 (en) p2x7 modulators
BR112013024953A2 (en) process for preparing self-ligating pigment particles, self-ligating pigment particle suspension, and, use of self-ligating pigment particle suspension
NZ627274A (en) Anesthetic compounds and related methods of use
MX368844B (en) Imidazoline derivatives, preparation methods thereof, and their applications in medicine.
BR112013027787A2 (en) compounds, pharmaceutical composition, method for treating a cell proliferative disorder, method for treating a neurological disorder, methods for inhibiting one or more kinases, method for inhibiting cell proliferation of cancer cells, method for inducing cancer cell death, method for to induce apoptosis of cancer cells, method to induce apoptosis in a cell and methods to produce compounds
EA201791738A1 (en) PROLIPOSOMAL TESTOSTERONE COMPOSITIONS
BR112015008552A2 (en) crystalline material, pharmaceutical composition, and process for the preparation of a crystalline material
AR092006A1 (en) PHCH CONTROLLED BY LOAD
UA112540C2 (en) A FILM MEDICINAL FORM CONTAINING THE FREE SILDENAFIL BASE AND THE METHOD OF OBTAINING THIS
UA117685C2 (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin
BR112014029286A2 (en) solid cosmetic composition, process for its production, product and cosmetic method
BR112012023660A2 (en) new methods to target cancer stem cells
BR112015031649A2 (en) Polyolefin / (meth) acrylic impact modifier and method for preparing the same
BR112013010376A2 (en) process for preparing calcium carbonate-containing composite particles, calcium carbonate-containing composite particles, and uses of a binder and composite particles
MY160829A (en) Powdered oil composition and production method thereof, and method of improving the functionality of the oil-in-water emulsion
BR112013032841A8 (en) Method for producing powders for inhalation
BR112015013322A2 (en) solid cosmetic composition, method for its production, product and cosmetic method
BR112014030452A2 (en) process for producing cell culture media

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/14 , A61J 3/02 , A61K 9/72 , A61K 31/137 , A61K 31/569 , A61K 47/26 , A61P 11/00 , A61P 11/06 , A61P 11/08

Ipc: A61K 9/16 (2006.01), A61K 31/137 (2006.01), A61K 3

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/02/2013, OBSERVADAS AS CONDICOES LEGAIS.